NO942367D0 - - Google Patents

Info

Publication number
NO942367D0
NO942367D0 NO942367A NO942367A NO942367D0 NO 942367 D0 NO942367 D0 NO 942367D0 NO 942367 A NO942367 A NO 942367A NO 942367 A NO942367 A NO 942367A NO 942367 D0 NO942367 D0 NO 942367D0
Authority
NO
Norway
Prior art keywords
plasminogen
lys
reperfusion
plasmin
administration
Prior art date
Application number
NO942367A
Other languages
English (en)
Norwegian (no)
Other versions
NO942367L (no
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO942367D0 publication Critical patent/NO942367D0/no
Publication of NO942367L publication Critical patent/NO942367L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • External Artificial Organs (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO942367A 1993-07-02 1994-06-21 Forhindring og behandling av ischemiske hendelser og reperfunsjonsskade resulterender derfra NO942367L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8803393A 1993-07-02 1993-07-02

Publications (2)

Publication Number Publication Date
NO942367D0 true NO942367D0 (de) 1994-06-21
NO942367L NO942367L (no) 1995-01-03

Family

ID=22208925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942367A NO942367L (no) 1993-07-02 1994-06-21 Forhindring og behandling av ischemiske hendelser og reperfunsjonsskade resulterender derfra

Country Status (19)

Country Link
US (2) US5520912A (de)
EP (1) EP0631786B1 (de)
JP (1) JP2784146B2 (de)
AT (2) AT407706B (de)
AU (1) AU680492B2 (de)
CA (1) CA2127199C (de)
CZ (1) CZ283352B6 (de)
DE (1) DE69411084T2 (de)
DK (1) DK0631786T3 (de)
ES (1) ES2119934T3 (de)
GR (1) GR3027778T3 (de)
HR (1) HRP940381B1 (de)
HU (1) HU217961B (de)
NO (1) NO942367L (de)
PL (1) PL304061A1 (de)
RU (1) RU2153353C2 (de)
SI (1) SI0631786T1 (de)
SK (1) SK281472B6 (de)
ZA (1) ZA944522B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
EP1062953A1 (de) * 1999-06-22 2000-12-27 Leuven Research & Development vzw Verwendung von Verbindungen, die Alpha2-Antiplasmin in vivo reduzieren, zur Herstellung einer Zusammensetzung zur Behandlung ischämischer Schlaganfälle
ATE349226T1 (de) 1998-09-29 2007-01-15 Leuven Res & Dev Vzw Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
EP1169055A4 (de) * 1999-01-19 2009-10-21 Bristol Myers Squibb Co Methode zur bestimmung von pflegeabläufen und vorbeugungsmassnahmen zur klinischen behandlung von wunden
US7184963B1 (en) 1999-01-19 2007-02-27 Bristol-Myers Squibb Company Method for determining care and prevention pathways for clinical management of wounds
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
DE10390418D2 (de) * 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
WO2004009773A2 (en) * 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
RU2341256C1 (ru) * 2007-03-26 2008-12-20 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ профилактики реперфузионных осложнений у пациентов, оперированных по поводу хронической ишемии нижних конечностей
RU2411911C1 (ru) * 2009-07-02 2011-02-20 Клиника государственного образовательного учреждения высшего профессионального образования "Челябинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"(Клиника ГОУ ВПО ЧелГМА Роздрава) Способ прогнозирования характера течения реперфузионного синдрома после поэтапного хирургического лечения сонных артерий у пациентов с симптомными бикаротидными стенозами
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2018107707A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
WO2018107688A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
RU2729788C2 (ru) * 2018-09-04 2020-08-12 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Пущинский научный центр биологических исследований Российской академии наук" Средство, его применение и способ повышения устойчивости организма млекопитающих к ишемически-реперфузионному поражению тонкого кишечника
CN113597313A (zh) 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
CN113677201B (zh) * 2019-04-12 2023-09-26 乌格勒克科学有限公司 用于修复肾脏的方法和装置
US20220183272A1 (en) * 2019-04-12 2022-06-16 Uglx Research Ab Method and apparatus for reconditioning organs
CN114642722A (zh) * 2020-12-18 2022-06-21 四川大学华西医院 纤溶酶原用于制备促进血管新生的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) * 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
AU600724B2 (en) * 1986-05-12 1990-08-23 Boehringer Ingelheim International Gmbh Novel combination
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
US5358936A (en) * 1990-08-03 1994-10-25 Paul Gordon Anionic furanose derivatives, methods of making and using the same
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen

Also Published As

Publication number Publication date
HRP940381A2 (en) 1997-04-30
DK0631786T3 (da) 1999-04-06
EP0631786B1 (de) 1998-06-17
AT407706B (de) 2001-05-25
US5597800A (en) 1997-01-28
HUT67225A (en) 1995-03-28
CZ161394A3 (en) 1995-01-18
ZA944522B (en) 1995-02-23
AU680492B2 (en) 1997-07-31
SI0631786T1 (en) 1998-10-31
JP2784146B2 (ja) 1998-08-06
PL304061A1 (en) 1995-01-09
CZ283352B6 (cs) 1998-03-18
GR3027778T3 (en) 1998-11-30
AU6485494A (en) 1995-01-12
HRP940381B1 (en) 1999-06-30
RU94022754A (ru) 1996-08-10
EP0631786A1 (de) 1995-01-04
HU9401983D0 (en) 1994-09-28
ATA131094A (de) 2000-10-15
SK281472B6 (sk) 2001-04-09
DE69411084T2 (de) 1998-12-03
CA2127199C (en) 2000-11-28
JPH07145076A (ja) 1995-06-06
SK79894A3 (en) 1995-05-10
DE69411084D1 (de) 1998-07-23
HU217961B (hu) 2000-05-28
ATE167400T1 (de) 1998-07-15
US5520912A (en) 1996-05-28
NO942367L (no) 1995-01-03
CA2127199A1 (en) 1995-01-03
RU2153353C2 (ru) 2000-07-27
ES2119934T3 (es) 1998-10-16

Similar Documents

Publication Publication Date Title
NO942367D0 (de)
GB9409281D0 (en) Transdermal device
NO885109D0 (no) FremgangsmŸte og middel for Ÿ forhindre blodpropp.
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
DE69432179D1 (de) Eine formulierung des gerinnungsfaktors viii
DE60139078D1 (de) Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser-sehkraftkorrektur-chirurgie
GR3019328T3 (en) Vampire bat salivary Plasminogen activator vPA-alpha 1
GR3017321T3 (en) Use of amino acids for the protection of and metabolic recovery of ischemic cardiac tissue.
DK0381640T3 (da) Thrombolytiske præparater
DK532886A (da) Farmaceutisk praeparat med thrombolytisk aktivitet og fremgangsmaade til fremstilling deraf
ES2033295T3 (es) Un metodo para preparar un activador de plasminogeno.
GABOVICH et al. STUDY OF OZONE TREATMENT OF THE DNIEPER WATER(IN RUSSIAN)
JPS6466130A (en) High polymer carcinostatic enhancer
Prevot et al. Reducing “DVT hard core” through veinous stimulation report on 300 hip arthtroplasties
SU1608870A1 (ru) Способ лечения кистозных новообразований челюсти

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application